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Abstract
Se metabolism in humans is not well characterised. Currently, the estimates of Se absorption, whole-body retention and excretion are being
obtained from balance and tracer studies. In the present study, we used gamma camera imaging to evaluate the whole-body retention and
distribution of radiolabelled selenomethionine (SeMet), the predominant form of Se present in foods. A total of eight healthy young men
participated in the study. After consumption of a meal containing 4 MBq [75Se]L-SeMet ([75Se]SeMet), whole-body gamma camera scanning
was performed for 45 min every hour over a 6 h period, every second hour for the next 18 h and once on each of the subsequent 6 d.
Blood, urine and faecal samples were collected to determine the plasma content of [75Se]SeMet as well as its excretion in urine and
faeces. Imaging showed that 87·9 (SD 3·3) % of the administered activity of [75Se]SeMet was retained within the body after 7 d. In contrast,
the measured excretion in urine and faeces for the 7 d period was 8·2 (SD 1·1) % of the activity. Time–activity curves were generated for the
whole body, stomach, liver, abdomen (other than the stomach and the liver), brain and femoral muscles. Gamma camera imaging allows
for the assessment of the postprandial absorption of SeMet. This technique may also permit concurrent studies of organ turnover of SeMet.
Key words: Selenomethionine: Absorption: Whole-body distribution: Gamma camera imaging
Se is recognised as a nutrient that is essential for human
health(1,2). An inadequate Se supply seems to be associated
with an increased risk of CVD(3,4). Other studies have reported
a relationship between low Se exposure and risk of
cancer(5–7). In foods and supplements, Se exists in a number
of organic and inorganic forms including selenomethionine
(SeMet), selenocysteine, selenate and selenite. The predomi-
nant form of Se in foods is organically bound, primarily in
the form of SeMet(8,9). Bioavailability and tissue distribution
depend on the form ingested. Thus, SeMet is more effective
in increasing the apparent Se status because it is non-specifi-
cally incorporated into proteins in place of methionine(10).
SeMet is a less-available metabolic source of Se compared
with selenite and selenate, since these only need to be
reduced to selenide to provide selenophosphate, the
precursor of selenocysteine, the active form of Se in seleno-
proteins(11). Despite this, organic forms are often preferred
in interventions, partly because they are less acutely toxic(8,9).
Intestinal absorption of inorganic and organic Se com-
pounds occurs via different routes and by different
mechanisms. Membrane transport proteins with the capacity
to mediate the uptake of organic forms of Se have been ident-
ified. Thus, studies have revealed that the selenoamino acids
SeMet, selenocysteine and methylselenocysteine are trans-
ported effectively by a suite of amino acid transporters(12).
The incorporation of dietary Se into selenoproteins
occurs through a series of interconvertions, many details of
which are still lacking. Se metabolites are excreted in urine,
faeces and breath mainly as selenosugars and methylated
compounds(13).
Human studies on Se absorption and metabolism have been
predominantly based on the recovery of ingested tracers in
blood, urine and faeces(14,15). A simple, direct method for
assessing Se absorption and turnover is not available.
Gamma camera imaging is currently being used to follow
the organ uptake of a variety of radiolabelled tracers for diag-
nostic purposes. Our hypothesis was that the gamma camera
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technique might as well constitute a useful imaging method
for following the absorption and turnover of SeMet. Therefore,
the objectives of the present study were to assess whether
gamma camera imaging after oral intake of radiolabelled
SeMet can be used to quantify the gastrointestinal absorption
capacity of SeMet and to follow its postprandial distribution
within the body.
Materials and methods
A total of eight healthy men (age 25 (SD 3) years, weight 77·2
(SD 5·3) kg, height 1·82 (SD 0·04) m, BMI 23·2 (SD 1·4) kg/m2
and plasma volume 3·31 (SD 0·16) litres) participated in the
study. All participating men had normal plasma Se levels
before the study (1·11 (SD 0·11)mmol/l). None of the partici-
pants had undergone abdominal surgery previously (other
than an appendectomy) or taken any medication. The present
study was conducted according to the guidelines laid down in
the Declaration of Helsinki, and all procedures involving
human subjects were approved by the Scientific Ethics Com-
mittees of the Capital Region of Denmark (protocol no.
H-3-2009-092) and the Danish Data Protection Agency
(journal no. 2009-41-3751). Written informed consent was
obtained from all the participants.
Procedure
After at least a 10 h fast, a cannula was inserted into the cubital
vein of the participants at 08.00 hours for blood sampling.
Then, whole-body transmission scanning was performed.
After having voided and discarded the urine, the partici-
pants ingested a [75Se]L-SeMet ([75Se]SeMet)-containing
meal between 08.45 and 09.00 hours. Immediately after
consumption of the meal, a whole-body emission scanning
was performed. The procedure was repeated every hour
over a 6 h period, every second hour for the next 18 h and
once at 09.00 hours on each of the subsequent 6 d. A total
of twenty-two emission scans were acquired from each
participant.
After each emission scanning session, a 10 ml blood sample
was drawn to follow the plasma concentration of 75Se. Starting
at 09.00 hours on the 1st day, urine was collected at 2 h
periods until 09.00 hours the next morning. Then, urine was
collected at 24 h periods for the next 6 d. Starting at 09.00
hours on the 1st day, faeces were sampled at 24 h periods
for the next 7 d.
[75Se]L-selenomethionine
[75Se]SeMet was produced and delivered by the Hevesy
Laboratory, DTU Nutech. The radionuclide, 75Se, was pro-
duced by neutron irradiation of 5 mg of natural Se metal. Neu-
tron irradiation for 4 weeks at the University of Missouri
Research Reactor Center, Columbia, MI, USA, yielded
687 MBq 75Se as measured at the start of [75Se]SeMet synthesis,
as described previously(16). A fraction of [75Se]SeMet obtained
from the synthesis was purified using preparative HPLC with
an aqueous 0·9 % NaCl solution as the eluent. After dilution
and sterile filtration, the final formulation contained 92 MBq
[75Se]SeMet in 30 ml of aqueous 0·9 % NaCl. The specific
activity was 10·9 GBq/mmol. The radionuclidic purity of the
product was measured with germanium detector spec-
troscopy, and no impurities were detected. The radiochemical
purity was determined to be .98 % by analytical HPLC.
[75Se]L-selenomethionine-containing meal
The [75Se]SeMet-containing meal comprised 2970 kJ (16 % pro-
tein, 28 % fat and 56 % carbohydrates) and consisted of black
bread, butter, chicken, cheese, jam, yogurt, muesli and 350 ml
of water with 4 MBq [75Se]SeMet comprising 29·0mg Se
(of which only 0·027 % was radioactive).
24 h diet regimen
Additional meals comprising 11 816 kJ were ingested after
emission scanning at 12.45, 16.45, 18.45, 20.45, 22.45, 02.45
and 06.45 hours. Because of the imaging procedures, blood
sampling and urine sample collection, the participants were
awake for longer periods of the night. Therefore, we found
that it was most convenient for the participants if three small
meals were served during the night. Every second hour, the
participants drank 350 ml of water.
Imaging system
Imaging was performed using a dual-head gamma camera
equipped with a single-slice computed tomography system
(Infinia VC HawkEye; General Electric Medical Systems) and
connected to a dedicated image processing system (Xeleris;
General Electric Medical Systems).
Transmission scanning
For the purpose of subject-specific attenuation correction, a
whole-body planar transmission image (X-ray scout image)
was acquired using the X-ray unit of the imaging system.
The image matrix had a size of 384 £ 2000 pixels, each
with a size of 1 mm2, and the total scanning time was
approximately 2 min. For the determination of an attenuation
correction map for 75Se, valid for the gamma photons detected
in the emission scanning windows, linear attenuation coeffi-
cients for soft tissue and bone were first calculated from the
reference data(17). Abundance-weighted averages of the
attenuation coefficient values for 136, 265 and 280 keV were
calculated for soft tissue and bone. The pixel values in the
acquired scout image were then rescaled by multiplication
to a factor determined from the weight of the participants,
by assuming a representative photon energy of 70 keV for
the X-ray bremsstrahlung spectrum and by performing a scal-
ing from the linear attenuation values of 70 keV to the photon
energies used for 75Se imaging(18).
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Fig. 1. Examples of emission (gamma camera) images after oral ingestion of [75Se]L-selenomethionine. (a) Raw non-corrected images. (b) Images corrected for
scattered gamma radiation, septal penetration of gamma radiation, and gamma ray attenuation and with the various regions of interest (whole body, stomach,
liver, abdomen other than the stomach and the liver, brain and femoral muscles) superposed.


















The distribution of 75Se was investigated by planar whole-
body emission scanning. Anterior and posterior projections
were acquired from the participants in the supine position.
Medium-energy, all-purpose collimators and 136 ^10 % and
272 ^12·5 % keV energy windows were used. The principal
gamma emissions in the 75Se decay that were detected in
these energy windows were 136, 265 and 280 keV with emis-
sion abundances of 0·6059, 0·5940 and 0·2519, respectively.
Whole-body images, composed of 256 £ 1024 pixels, each
measuring 5·76 mm2, were acquired at a scanning speed of
5 cm/min, implying a total scanning time of 45 min.
Image correction for scatter, septal penetration and
photon attenuation
For reliable quantification of 75Se distribution, planar whole-
body emission images were compensated for physical
decay, scatter contribution, septal penetration and photon
attenuation. In brief, the raw anterior–posterior images were
corrected for scatter and septal penetration by means of a
deconvolution procedure, in which the scatter point-spread
functions were determined by Monte Carlo simulation for
the specific camera system, radionuclide and average thick-
ness of the participants over the abdominal region(19). From
the obtained primary count rate images, geometric mean
images were calculated by pixel-by-pixel multiplication of
the anterior and mirrored posterior images. Since the partici-
pants were allowed to move between transmission and emis-
sion scanning, co-registration of the emission images was
necessary to enable pixel-based activity quantification. For
this purpose, an automatic co-registration method was
applied(20), in which the 5 h emission image was first co-regis-
tered to the attenuation correction map and the remaining
emission images were registered to the co-registered 5 h
image. The 5 h image was chosen as a reference since the
activity had by then distributed within the body and thus
exhibited characteristics favourable for registration to the
attenuation correction map. Correction for photon attenuation
was performed by pixel-by-pixel multiplication of the regis-
tered couples of geometric mean images and the attenuation
map(18). The scatter-, septal penetration- and attenuation-com-
pensated images were converted from counts/s to activity
using a measured value of the system sensitivity (counts/s
per MBq). This value was determined by imaging a 75Se
source located 10 cm from the surface of the collimator,
using the collimator and energy windows used for emission
scanning(19). Finally, the obtained activity projection images
were analysed for activity in different structures using two-
dimensional regions of interest that were delineated manually
by the same observer in all the images.
Plasma, urine and faecal sample analyses
All blood samples were immediately centrifuged for 10 min at
1000 g, and plasma was stored until analysis. On completion
of the study, the weight of each urine and faecal portion
was recorded. The faecal portions were homogenised with
known amounts of water, and aliquots of urine and faeces
were stored for later analysis. For the measurement of 75Se
activity, 3 ml aliquots of plasma, urine and homogenised
faecal samples and an appropriate dilution of the stock sol-
ution of [75Se]SeMet were counted for 30 min in a gamma
well counter (Wizard 1480; Wallac). For conversion into
counts for total plasma volume, the total plasma volume of
each participant was estimated from height and weight data
according to tabled references(21). All counts were corrected
for physical decay, converted into Bq and expressed as the
percentage of the administered activity.
Statistical analysis
The whole-body loss of 75Se activity after 7 d, as estimated
from image data, and the measured excretion of 75Se activity
in urine and faeces after 7 d were compared using the
paired t test. A P value ,0·05 was considered significant.
Dosimetry
Each participant received an effective absorbed dose of
10·6 mSv, of which 0·2 mSv was from transmission scanning
and 10·4 mSv from [75Se]SeMet. In contrast, the normal back-
ground radiation in the UK results in a yearly average effective
absorbed dose of 2–3 mSv and a standard thorax X-ray com-
puted tomography results in an effective absorbed dose of
about 10 mSv.
Results
The examples of raw non-corrected emission (gamma camera)
images and the corresponding corrected images with
superposed regions of interest are shown in Fig. 1. In all the
participants, the accumulation of 75Se activity permitted
reliable delineation of the body contour, stomach and liver.
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Fig. 2. Example of time–activity curves derived from the various regions of
interest drawn on the corrected emission (gamma camera) images after oral
ingestion of [75Se]L-selenomethionine. , Whole body; , stomach; ,
liver; , abdomen other than the stomach and the liver; , brain; ,
femoral muscles.

















The resolution of the images was so low that we could not
delineate the spleen, pancreas, small intestine or colon in
any of the images. In the images of some of the participants,
we could see the kidneys, but only in the posterior view.
The body contour judged the delineation of areas over the
brain, femoral muscles and abdomen (other than the stomach
and the liver). Fig. 2 shows the retention of 75Se activity in the
various regions of interest v. time for one participant. For one
representative participant, the total plasma activity of 75Se as a
function of time, as well as the accumulated excretion of 75Se
in urine and faeces v. time, is shown in Fig. 3. Fig. 4 shows the
whole-body loss of 75Se activity against time as estimated from
the quantified emission (gamma camera) images, as well as
the accumulated excretion of 75Se in urine and faeces v.
time, for one participant. After 7 d, the imaging showed that
87·9 (SD 3·3) % of the administered activity was retained
within the body; that is, 12·1 (SD 3·3) % of the activity was
lost from the body. In contrast, the accumulated excretion in
urine and faeces was 8·2 (SD 1·1) % of the administered activity
after 7 d (P¼0·008).
Discussion
In 1961, Blau(22) introduced [75Se]SeMet as a radiolabelled
agent for gamma camera imaging of the pancreas. This
amino acid was selected for examination because of its high
rate of incorporation into pancreatic enzymes after intrave-
nous injection. During the following decade, [75Se]SeMet was
used for the scintigraphic detection of pancreatic and para-
thyroid adenomas as well as lymphomas(23–25). However,
the 120 d half-life of 75Se limited the acceptable administered
activity and consequently the quality of the acquired images.
As a result, the procedure was outdistanced by the new and
much more efficient ultrasonographic and X-ray computed
tomography methods. Since then, the imaging quality of
the gamma camera has improved, and we found it, therefore,
relevant to evaluate the performance of scintigraphy for
recording the whole-body retention and distribution of oral
[75Se]SeMet.
SeMet is absorbed rapidly and almost completely from the
normal human intestine and is an important organic nutri-
tional source of Se that is essential for human health(1,2).
Much of the Se in plants is present in small selenoamino
acid compounds derived from SeMet and selenocysteine,
whereas animal-derived food products seem to contain Se
mainly as SeMet and selenocysteine in proteins(8,9). SeMet
can be a constituent part of general protein synthesis(26).
Through the intermediate metabolite selenide, Se from nutri-
tional SeMet is excreted predominantly in the urine in the
form of selenosugars(27).
In a previous study carried out by Griffiths et al.(14), whole-
body counting and urinary and faecal losses were used to
follow the whole-body retention of an oral dose of [75Se]SeMet
in four healthy women. After 7 d, the estimated whole-body
retention from the measured loss in urine and faeces was
90–92 %, whereas whole-body counting showed a slightly
lower retention. Our findings are in accordance with these
previous observations. In parallel with this, the present ima-
ging technique showed a whole-body loss of [75Se]SeMet on
day 7 that was slightly but significantly (P¼0·008) higher
than the detected accumulated loss in urine and faeces after
7 d (Fig. 4). The reason for this difference is not clear, but at
least some of the discrepancy may have resulted from the
fact that we did not measure the amount of 75Se that was
excreted in the breath. Besides, incomplete sampling of
urine and faeces or imperfect image-based corrections for
photon attenuation and scatter may be possible reasons. The
peak 75Se plasma concentration after 4–6 h in the present
study is within the range found by Griffiths et al.(14). Thus,
gamma camera recording of the whole-body retention of
[75Se]SeMet seems reliable for evaluating the overall intestinal
absorption of SeMet.
For all the participants, we could clearly delineate the body
contour, stomach and liver in the corrected images (Fig. 1),
and presumably, therefore, the corresponding time–activity
Time (h)





























Fig. 4. Example of the time course of the whole-body loss ( ) of 75Se as
estimated from the corrected emission (gamma camera) images and corre-
sponding accumulated excretion of 75Se in urine and faeces ( ) after oral
ingestion of [75Se]L-selenomethionine. After 7 d, the whole-body loss of 75Se
as found by imaging was significantly higher than the amount excreted in the
urine and faeces in a group of eight healthy men (P¼0·008).
Time (h)


























Fig. 3. Example of time–activity curves derived from the analysis of plasma
( ), urine ( ) and faecal ( ) samples after oral ingestion of [75Se]L-sele-
nomethionine.

















curves (Figs. 2–4) are valid. Based on the reported concen-
trations of 75Se activity in tissue collected at surgery or autopsy
after intravenous injection of [75Se]SeMet, the total liver con-
tent of 75Se seems to be 15–20 % of the administered activity
after 7 d(28,29), a value that is in line with the present finding.
The time–activity curves obtained for the liver probably
reflect a complex interplay between the intestinal absorption
of [75Se]SeMet, liver uptake and metabolism of [75Se]SeMet,
and liver release of 75Se-containing compounds. In some clini-
cal settings, therefore, a sequential gamma camera imaging
procedure might prove useful for monitoring the aspects of
parenchymatous liver function. Unless [75Se]SeMet is absorbed
from the stomach, which is unlikely, the time–activity curves
for the stomach simply reflect gastric emptying of the tracer.
Our data suggest a low uptake of SeMet, other Se-containing
compounds or free Se in the brain and femoral muscles.
The present study has some limitations. First, the diet regi-
men aimed to reduce the effect of variations in meal compo-
sition and gastrointestinal motility on the absorption of
[75Se]SeMet. For practical reasons, the regimen was followed
only for the first 24 h, and it is, therefore, conceivable that
changing the intake of Se and SeMet during the rest of the
study period increased the inter-subject variations in deter-
mined retention and excretion values. We did not measure
the Se content of the initial meals and the plasma concen-
tration of Se during the study. Possibly, inter-subject variations
in Se status could explain some of the apparent differences in
Se kinetics. However, the main objective of the study was to
assess the overall efficacy of the imaging technique. Second,
free amino acids can be absorbed via different amino acid
transporters with certain group specificities in the small intes-
tine(2). Thus, normal whole-body retention of oral [75Se]SeMet
only rules out an impaired intestinal absorption of that specific
amino acid in its free form. Third, as proteins and free amino
acids behave differently at several digestive steps (such as gas-
tric emptying and dietary protein hydrolysis and absorption),
the time course of the appearance of a free amino acid in
the plasma can be different from that of the same amino
acid bound to proteins(30). Consequently, the metabolic fate
of free [75Se]SeMet does not necessarily reflect that of SeMet
bound to dietary proteins. Fourth, quite arbitrarily, we only
followed our participants for 7 d. In all the participants, how-
ever, we observed a slow and almost linear decrease in liver/
abdominal 75Se levels after the initial peak. Therefore, it is not
likely that imaging beyond 7 d would have added substantially
to our observations. Lastly, our presentation would profit from
compartmental modelling of the data, if possible. Thus, we
hoped that the data could be used to confirm or improve
some of the modelling-based variables found by Swanson
et al.(31) and Wastney et al.(15). However, only the stomach
and the liver were clearly depicted in all the images, leaving
the data obtained for the liver only relevant for kinetic anal-
ysis. Furthermore, the time resolution of the initial part of
the time–activity curves obtained for the liver was too low
for proper use. Future dynamic studies with, for instance,
1 min image acquisitions of the abdominal region for a few
hours together with simultaneous sampling of the plasma
will probably yield information about the initial SeMet turn-
over that can be used for reliable compartmental modelling.
Summary and perspectives
Whole-body gamma camera imaging with appropriate correc-
tion for scatter, septal penetration and photon attenuation pro-
vides reliable recordings of the intestinal absorption of SeMet.
Therefore, this method potentially provides the opportunity to
non-invasively explore the effects of food composition, gastro-
intestinal motility, and gastrointestinal resection or bypass on
the intestinal absorption of SeMet. Furthermore, the technique
seems to allow postprandial recordings of the whole-body dis-
tribution of SeMet and thereby provides data that could be
used to confirm or improve the existing models of human
SeMet metabolism.
The overall strength of the gamma camera technique is its
capability of tracing quantitatively small amounts of
gamma ray-emitting substances in vivo. Thus, the technique
allows the tracing of physiological amounts of radio-
labelled nutrients or food elements other than SeMet. The
weaknesses of the method are the restricted availability and
exposure to radiation.
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